Muestra métricas de impacto externas asociadas a la publicación. Para mayor detalle:
| Indexado |
|
||||
| DOI | 10.1016/J.IJANTIMICAG.2009.06.005 | ||||
| Año | 2009 | ||||
| Tipo | revisión |
Citas Totales
Autores Afiliación Chile
Instituciones Chile
% Participación
Internacional
Autores
Afiliación Extranjera
Instituciones
Extranjeras
Meticillin-resistant Staphylococcus aureus (MRSA) has become a serious threat to public health worldwide. Ongoing surveillance is essential to support infection control committees and clinicians in the prevention and treatment of infection. However, in Latin America, resources for monitoring the changing epidemiology of MRSA remain limited. In this article, we review the current situation of MRSA in Latin America in order to highlight the need for a more harmonised effort to improve its management. Literature in the PubMed and SciELO databases as well as the website of the Pan American Health Organization were searched for articles and information about the epidemiology of MRSA in Latin America. MRSA is already the leading cause of nosocomial infection in the Latin American region, and the number of reports of community-acquired MRSA infections is also rising. However, the extent of the problem is not fully understood, especially since data tend to come from large hospitals whereas much of the population is served by small community healthcare centres that do not have extensive facilities for performing microbiological surveillance. In conclusion, wider-reaching and co-ordinated programmes to provide regular MRSA surveillance reports are required across the Latin American region. (C) 2009 Elsevier B.V. and the International Society of Chemotherapy. All rights reserved.
| Ord. | Autor | Género | Institución - País |
|---|---|---|---|
| 1 | Gkiokas, George | Hombre |
Ctr Med Caracas - Venezuela
Centro Medico Docente La Trinidad - Venezuela |
| 2 | Mejia, Carlos | Hombre |
Roosevelt Hosp - Guatemala
Roosevelt Hospital Guatemala - Guatemala |
| 3 | Isturiz, Raul | Hombre |
Ctr Med Caracas - Venezuela
Centro Medico Docente La Trinidad - Venezuela |
| 4 | ÁLVAREZ, CARLOS | Hombre |
Hosp San Ignacio - Colombia
Pontificia Univ Javeriana - Colombia Pontificia Universidad Javeriana - Colombia |
| 5 | BAVESTRELLO-FERNANDEZ, LUIS | Hombre |
Clínica Reñaca - Chile
Clin Renaca - Chile |
| 6 | Gotuzzo, E. | Hombre |
UNIV PERUANA CAYETANO HEREDIA - Perú
Universidad Peruana Cayetano Heredia - Perú |
| 7 | Labarca, Jaime | Hombre |
Pontificia Universidad Católica de Chile - Chile
|
| 8 | Luna, Carlos | Hombre |
UNIV BUENOS AIRES - Argentina
Universidad de Buenos Aires - Argentina |
| 9 | Rodriguez-Noriega, E. | Hombre |
Univ Guadalajara - México
Hospital Civil de Guadalajara - México Universidad de Guadalajara - México |
| 10 | COSTA-SALLES, MAURO JOSE | Hombre |
Hosp Irmandade Santa Casa Misericordia Sao Paulo - Brasil
Chandru - Brasil |
| 11 | Zurita, Jeannete | Mujer |
Hosp Vozandes - Ecuador
Hospital Vozandes - Ecuador |
| 12 | Seas, Carlos | Hombre |
UNIV PERUANA CAYETANO HEREDIA - Perú
Universidad Peruana Cayetano Heredia - Perú |
| Fuente |
|---|
| Pfizer Inc. |
| GlaxoSmithKline |
| Bristol-Myers Squibb |
| Abbott Laboratories |
| Pfizer |
| Johnson and Johnson |
| Merck |
| Merck Sharp and Dohme |
| Janssen-Cilag |
| Wyeth |
| Cerexa |
| Schering-Plough |
| Baxter International |
| Choice Pharma |
| CML |
| Agradecimiento |
|---|
| Pfizer Inc. (New York, NY) provided support for meetings of the Latin American Working Group on Gram-Positive Resistance. Members of the Working Group received honoraria for attendance at the meetings. Pfizer Inc. had no involvement in the study design, in the collection, analysis and interpretation of the data, or in the decision to submit the article for publication. The support provided by Choice Pharma (Hitchin, UK), funded by Pfizer Inc., consisted solely of manuscript formatting and writing assistance. |
| Funding: Pfizer Inc. (New York, NY) provided support for meetings of the Latin American Working Group on Gram-Positive Resistance. Members of the Working Group received honoraria for attendance at the meetings. Pfizer Inc. had no involvement in the study design, in the collection, analysis and interpretation of the data, or in the decision to submit the article for publication. The support provided by Choice Pharma (Hitchin, UK), funded by Pfizer Inc., consisted solely of manuscript formatting and writing assistance. |